PITTSBURGH, Dec. 18, 2025 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...

Have you ever wondered why the contraceptive landscape is so female-centric? There are a number of factors to blame ...

Choosing birth control is deeply personal. An expert explains how women can assess their health, lifestyle, fertility goals, and safety needs to find the right contraceptive method.

(MENAFN- Market Press Release) November 25, 2025 2:59 am - The Transdermal Contraceptive Patches Market, valued at USD 800 million in 2025, is set to grow at a 6% CAGR through 2032. Global Transdermal ...

For years, Danish doctors inserted intrauterine devices in Greenlandic girls and women without their consent, part of a painful legacy of mistreatment. By Jeffrey Gettleman and Maya Tekeli The prime ...

Afaxys, a sexual and reproductive healthcare-focused company, secured $8 million in funding, including a $3 million program-related investment from the David and Lucile Packard Foundation and a $5 ...

EE: Ethinyl estradiol; LNG: Levonorgestrel; OC: Oral contraceptive; RR: Relative risk; VTE: Venous thromboembolism. Transdermal contraceptive patches provide a more convenient delivery system for ...

Viatris Inc. (NASDAQ:VTRS) on Thursday, released data from Phase 3 study evaluating the contraceptive efficacy and safety of XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 ...